{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:43:02Z","timestamp":1788846182965,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Opinion Statement<\/jats:title>\n                  <jats:p>Peritoneal metastases (PM) in small bowel neuroendocrine tumors (SBNET) are challenging. These patients have worse oncologic outcomes and may have symptoms related to mechanical obstruction and hormone production. Difficult decisions apply in diagnosis, surgical selection, postoperative systemic therapy, and surveillance. To aid in these decisions, we routinely recommend obtaining somatostatin receptor based functional imaging (i.e. DOTA PET\/CT) and arterial and venous phase CT preoperatively to evaluate disease burden and guide surgical planning. Disease biology should also guide surgical management. The presence of synchronous liver metastases should not exclude patients from surgery. For patients with PM and grade 1 or 2 well differentiated SBNETs, we recommend aggressive surgical cytoreduction with the goal of a completeness of cytoreduction (CC) of 0 or 1 and &gt;\u200970% cytoreduction of liver metastases. For high grade (G3) well differentiated SBNETs, surgical intervention may still be considered. In patients where the extent of disease does not allow for effective cytoreduction, or where patient comorbidities preclude extensive surgery, palliative surgeries or interventions may be preferred. Postoperatively, radiologic surveillance is important to evaluate for disease progression. Some SBNET patients presenting without PM are at risk of developing PM in follow-up, especially those with liver metastases or high T stage. In patients with progression or inoperable disease, systemic therapy including somatostatin analogs (SSAs), chemotherapy or peptide receptor radionuclide therapy (PRRT) may be potential options, although the latter may pose increased risk of bowel obstruction. When cytoreducton and systemic therapy are no longer options, palliative measures should be employed. Because of this complexity, management of PM in SBNET patients is a multidisciplinary collaborative effort.<\/jats:p>","DOI":"10.1007\/s11864-025-01364-y","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T11:40:46Z","timestamp":1760355646000},"page":"1023-1032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Options and Considerations in the Management of Peritoneal Disease in Patients with Small Bowel Neuroendocrine Tumors"],"prefix":"10.1007","volume":"26","author":[{"given":"Jeremy","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udhayvir S.","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"issue":"2","key":"1364_CR1","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000335587","volume":"95","author":"M Falconi","year":"2012","unstructured":"Falconi M, Bartsch DK, Eriksson B, Kloppel G, Lopes JM, O\u2019Connor JM, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95(2):120\u201334. https:\/\/doi.org\/10.1159\/000335587.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"1364_CR2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","volume":"46","author":"JR Howe","year":"2017","unstructured":"Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, et al. The surgical management of small bowel neuroendocrine tumors: consensus guidelines of the North American neuroendocrine tumor society. Pancreas. 2017;46(6):715\u201331. https:\/\/doi.org\/10.1097\/MPA.0000000000000846.","journal-title":"Pancreas"},{"key":"1364_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae343","author":"M Del Olmo-Garcia","year":"2025","unstructured":"Del Olmo-Garcia M, Hernandez-Rienda L, Garcia-Carbonero R, Hernando J, Custodio A, Anton-Pascual B, et al. Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study. Oncologist. 2025. https:\/\/doi.org\/10.1093\/oncolo\/oyae343.","journal-title":"Oncologist"},{"issue":"1","key":"1364_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.surg.2020.03.030","volume":"169","author":"SM Wonn","year":"2021","unstructured":"Wonn SM, Limbach KE, Pommier SJ, Ratzlaff AN, Leon EJ, McCully BH, et al. Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors. Surgery. 2021;169(1):168\u201374. https:\/\/doi.org\/10.1016\/j.surg.2020.03.030.","journal-title":"Surgery"},{"issue":"8","key":"1364_CR5","doi-asserted-by":"publisher","first-page":"5370","DOI":"10.1245\/s10434-024-15316-7","volume":"31","author":"H Gudmundsdottir","year":"2024","unstructured":"Gudmundsdottir H, Fogliati A, Grotz TE, Thiels CA, Warner SG, Smoot RL, et al. Value of surgical cytoreduction in patients with small intestinal neuroendocrine tumors metastatic to the liver and peritoneum. Ann Surg Oncol. 2024;31(8):5370\u20136. https:\/\/doi.org\/10.1245\/s10434-024-15316-7.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"1364_CR6","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1245\/s10434-016-5734-x","volume":"24","author":"A Madani","year":"2017","unstructured":"Madani A, Thomassen I, van Gestel Y, van der Bilt JDW, Haak HR, de Hingh I, et al. Peritoneal metastases from gastroenteropancreatic neuroendocrine tumors: Incidence, risk factors and prognosis. Ann Surg Oncol. 2017;24(8):2199\u2013205. https:\/\/doi.org\/10.1245\/s10434-016-5734-x.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"1364_CR7","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.17219\/acem\/126290","volume":"29","author":"P Gut","year":"2020","unstructured":"Gut P, Czarnywojtek A, Ruchala M. Chromogranin A assessment in patients with neuroendocrine neoplasm of the small bowel and carcinoid syndrome treated with somatostatin analogues. Adv Clin Exp Med. 2020;29(11):1319\u201324. https:\/\/doi.org\/10.17219\/acem\/126290.","journal-title":"Adv Clin Exp Med"},{"issue":"4","key":"1364_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000286700","volume":"91","author":"R Kianmanesh","year":"2010","unstructured":"Kianmanesh R, Ruszniewski P, Rindi G, Kwekkeboom D, Pape UF, Kulke M, et al. ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology. 2010;91(4):333\u201340. https:\/\/doi.org\/10.1159\/000286700.","journal-title":"Neuroendocrinology"},{"issue":"4","key":"1364_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/PAS.0000000000001225","volume":"43","author":"MF Wright","year":"2019","unstructured":"Wright MF, Cates J, Gonzalez RS, Das S, Berlin JD, Shi C. Impact of peritoneal metastasis on survival of patients with small intestinal neuroendocrine tumor. Am J Surg Pathol. 2019;43(4):559\u201363. https:\/\/doi.org\/10.1097\/PAS.0000000000001225.","journal-title":"Am J Surg Pathol"},{"issue":"13","key":"1364_CR10","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.addr.2007.08.008","volume":"59","author":"SP Evanko","year":"2007","unstructured":"Evanko SP, Tammi MI, Tammi RH, Wight TN. Hyaluronan-dependent pericellular matrix. Adv Drug Deliv Rev. 2007;59(13):1351\u201365. https:\/\/doi.org\/10.1016\/j.addr.2007.08.008.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"1364_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4251\/wjgo.v2.i1.12","volume":"2","author":"S Kusamura","year":"2010","unstructured":"Kusamura S, Baratti D, Zaffaroni N, Villa R, Laterza B, Balestra MR, et al. Pathophysiology and biology of peritoneal carcinomatosis. World J Gastrointest Oncol. 2010;2(1):12\u20138. https:\/\/doi.org\/10.4251\/wjgo.v2.i1.12.","journal-title":"World J Gastrointest Oncol"},{"issue":"7","key":"1364_CR12","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/0008-5472.CAN-07-5167","volume":"68","author":"K Sawada","year":"2008","unstructured":"Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008;68(7):2329\u201339. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5167.","journal-title":"Cancer Res"},{"issue":"6","key":"1364_CR13","doi-asserted-by":"publisher","first-page":"4571","DOI":"10.3892\/ol.2017.6063","volume":"13","author":"N Christou","year":"2017","unstructured":"Christou N, Perraud A, Blondy S, Jauberteau MO, Battu S, Mathonnet M. E-cadherin: a potential biomarker of colorectal cancer prognosis. Oncol Lett. 2017;13(6):4571\u20136. https:\/\/doi.org\/10.3892\/ol.2017.6063.","journal-title":"Oncol Lett"},{"issue":"6","key":"1364_CR14","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.21873\/anticanres.16416","volume":"43","author":"AM Sihombing","year":"2023","unstructured":"Sihombing AM, Murata S, Shimoji M, Miyake T, Takebayashi K, Kodama H, et al. CD44-positive cancer stem-like cells as a potential source of peritoneal metastasis after surgery. Anticancer Res. 2023;43(6):2491\u2013500. https:\/\/doi.org\/10.21873\/anticanres.16416.","journal-title":"Anticancer Res"},{"issue":"10","key":"1364_CR15","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/cas.12765","volume":"106","author":"F Tjhay","year":"2015","unstructured":"Tjhay F, Motohara T, Tayama S, Narantuya D, Fujimoto K, Guo J, et al. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer. Cancer Sci. 2015;106(10):1421\u20138. https:\/\/doi.org\/10.1111\/cas.12765.","journal-title":"Cancer Sci"},{"issue":"2","key":"1364_CR16","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1016\/j.clcc.2021.11.008","volume":"21","author":"F Soliman","year":"2022","unstructured":"Soliman F, Ye L, Jiang W, Hargest R. Targeting hyaluronic acid and peritoneal dissemination in colorectal cancer. Clin Colorectal Cancer. 2022;21(2):e126\u201334. https:\/\/doi.org\/10.1016\/j.clcc.2021.11.008.","journal-title":"Clin Colorectal Cancer"},{"issue":"1\u20132","key":"1364_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10555-011-9337-5","volume":"31","author":"S Masoumi Moghaddam","year":"2012","unstructured":"Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev. 2012;31(1\u20132):143\u201362. https:\/\/doi.org\/10.1007\/s10555-011-9337-5.","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"1364_CR18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cncr.11105","volume":"97","author":"IM Modlin","year":"2003","unstructured":"Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934\u201359. https:\/\/doi.org\/10.1002\/cncr.11105.","journal-title":"Cancer"},{"issue":"3","key":"1364_CR19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.soc.2021.02.004","volume":"30","author":"J Bleicher","year":"2021","unstructured":"Bleicher J, Lambert LA. A palliative approach to management of peritoneal carcinomatosis and malignant ascites. Surg Oncol Clin N Am. 2021;30(3):475\u201390. https:\/\/doi.org\/10.1016\/j.soc.2021.02.004.","journal-title":"Surg Oncol Clin N Am"},{"issue":"3","key":"1364_CR20","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.soc.2018.02.008","volume":"27","author":"LA Lambert","year":"2018","unstructured":"Lambert LA, Hendrix RJ. Palliative management of advanced peritoneal carcinomatosis. Surg Oncol Clin N Am. 2018;27(3):585\u2013602. https:\/\/doi.org\/10.1016\/j.soc.2018.02.008.","journal-title":"Surg Oncol Clin N Am"},{"key":"1364_CR21","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-18374-7","author":"J Chang","year":"2025","unstructured":"Chang J, Borbon LC, Sherman SK, Ear PH, Bellizzi AM, Dillon JS, et al. Risk factors and prognosis of peritoneal metastases in small bowel neuroendocrine tumor patients. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-025-18374-7.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1364_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-019-1730-5","volume":"17","author":"L Liang","year":"2019","unstructured":"Liang L, Wang W, Zhou N, Guo J, Lu Y, Xu H, et al. Value of preoperative ultrasound in evaluating the peritoneal cancer index of Pseudomyxoma peritonei. World J Surg Oncol. 2019;17(1):192. https:\/\/doi.org\/10.1186\/s12957-019-1730-5.","journal-title":"World J Surg Oncol"},{"issue":"9","key":"1364_CR23","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.ultrasmedbio.2017.02.016","volume":"43","author":"Z Qi","year":"2017","unstructured":"Qi Z, Zhang Y, Dai Q, Xia Y, Jiang Y. Peritoneal carcinomatosis in primary ovarian cancer: ultrasound detection and comparison with computed tomography. Ultrasound Med Biol. 2017;43(9):1811\u20139. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2017.02.016.","journal-title":"Ultrasound Med Biol"},{"key":"1364_CR24","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.5114\/pjr.2023.125027","volume":"88","author":"MA Szadkowska","year":"2023","unstructured":"Szadkowska MA, Palucki J, Cieszanowski A. Diagnosis and treatment of peritoneal carcinomatosis - a comprehensive overview. Pol J Radiol. 2023;88:e89\u201397. https:\/\/doi.org\/10.5114\/pjr.2023.125027.","journal-title":"Pol J Radiol"},{"issue":"1","key":"1364_CR25","doi-asserted-by":"publisher","DOI":"10.5334\/jbsr.2921","volume":"107","author":"S Kose","year":"2023","unstructured":"Kose S. Role of computed tomography in the evaluation of peritoneal carcinomatosis. J Belg Soc Radiol. 2023;107(1):27. https:\/\/doi.org\/10.5334\/jbsr.2921.","journal-title":"J Belg Soc Radiol"},{"issue":"4","key":"1364_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jviscsurg.2018.01.002","volume":"155","author":"A Dohan","year":"2018","unstructured":"Dohan A, Hobeika C, Najah H, Pocard M, Rousset P, Eveno C. Preoperative assessment of peritoneal carcinomatosis of colorectal origin. J Visc Surg. 2018;155(4):293\u2013303. https:\/\/doi.org\/10.1016\/j.jviscsurg.2018.01.002.","journal-title":"J Visc Surg"},{"issue":"18","key":"1364_CR27","first-page":"5969","volume":"50","author":"JCKL Reubi","year":"1990","unstructured":"Reubi JCKL, Waser B, Nagorney DM, Heitz PU, Charboneau CW, Reading CC, Moertel C. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990;50(18):5969\u201377.","journal-title":"Cancer Res"},{"issue":"6","key":"1364_CR28","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00268-011-1296-z","volume":"36","author":"O Norlen","year":"2012","unstructured":"Norlen O, Stalberg P, Oberg K, Eriksson J, Hedberg J, Hessman O, et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg. 2012;36(6):1419\u201331. https:\/\/doi.org\/10.1007\/s00268-011-1296-z.","journal-title":"World J Surg"},{"issue":"3","key":"1364_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.path.2020.04.002","volume":"13","author":"RS Gonzalez","year":"2020","unstructured":"Gonzalez RS. Diagnosis and management of gastrointestinal neuroendocrine neoplasms. Surg Pathol Clin. 2020;13(3):377\u201397. https:\/\/doi.org\/10.1016\/j.path.2020.04.002.","journal-title":"Surg Pathol Clin"},{"issue":"2","key":"1364_CR30","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.jss.2014.05.031","volume":"190","author":"JE Maxwell","year":"2014","unstructured":"Maxwell JE, Sherman SK, Menda Y, Wang D, O\u2019Dorisio TM, Howe JR. Limitations of somatostatin scintigraphy in primary small bowel neuroendocrine tumors. J Surg Res. 2014;190(2):548\u201353. https:\/\/doi.org\/10.1016\/j.jss.2014.05.031.","journal-title":"J Surg Res"},{"issue":"2","key":"1364_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.soc.2019.11.006","volume":"29","author":"AT Scott","year":"2020","unstructured":"Scott AT, Howe JR. Management of small bowel neuroendocrine tumors. Surg Oncol Clin N Am. 2020;29(2):223\u201341. https:\/\/doi.org\/10.1016\/j.soc.2019.11.006.","journal-title":"Surg Oncol Clin N Am"},{"issue":"10","key":"1364_CR32","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1097\/RLU.0000000000000533","volume":"39","author":"J Kunikowska","year":"2014","unstructured":"Kunikowska J, Pawlak D, Kolasa A, Mikolajczak R, Krolicki L. A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET\/CT uptake by primary site-dependent neuroendocrine tumor metastasis. Clin Nucl Med. 2014;39(10):855\u201361. https:\/\/doi.org\/10.1097\/RLU.0000000000000533.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"1364_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2217\/ije.14.40","volume":"2","author":"JE Maxwell","year":"2015","unstructured":"Maxwell JE, Howe JR. Imaging in neuroendocrine tumors: an update for the clinician. Int J Endocr Oncol. 2015;2(2):159\u201368. https:\/\/doi.org\/10.2217\/ije.14.40.","journal-title":"Int J Endocr Oncol"},{"key":"1364_CR34","unstructured":"Chang JBL, Sherman SK, Ear PH, Bellizzi AM, Dillon JS, Howe JR. Risk factors and prognosis of peritoneal metastases in small bowel neuroendocrine tumor patients. Ann Surg Oncol. In Review."},{"issue":"2","key":"1364_CR35","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1245\/s10434-024-16463-7","volume":"32","author":"LC Borbon","year":"2025","unstructured":"Borbon LC, Sherman SK, Breheny PJ, Chandrasekharan C, Menda Y, Bushnell D, et al. Peptide receptor radionuclide therapy improves survival in patients who progress after resection of gastroenteropancreatic neuroendocrine tumors. Ann Surg Oncol. 2025;32(2):1136\u201348. https:\/\/doi.org\/10.1245\/s10434-024-16463-7.","journal-title":"Ann Surg Oncol"},{"issue":"32","key":"1364_CR36","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1200\/JCO.23.01529","volume":"41","author":"JD Rivero","year":"2023","unstructured":"Rivero JD, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, et al. Systemic therapy for tumor control in metastatic Well-Differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline. J Clin Oncol. 2023;41(32):5049\u201367. https:\/\/doi.org\/10.1200\/JCO.23.01529.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1364_CR37","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1245\/s10434-020-09566-4","volume":"28","author":"CG Tran","year":"2021","unstructured":"Tran CG, Sherman SK, Howe JR. The landmark series: management of small bowel neuroendocrine tumors. Ann Surg Oncol. 2021;28(5):2741\u201351. https:\/\/doi.org\/10.1245\/s10434-020-09566-4.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1364_CR38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1245\/s10434-022-12643-5","volume":"30","author":"IA Ziogas","year":"2023","unstructured":"Ziogas IA, Tasoudis PT, Borbon LC, Sherman SK, Breheny PJ, Chandrasekharan C, et al. Surgical management of G3 gastroenteropancreatic neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Surg Oncol. 2023;30(1):148\u201360. https:\/\/doi.org\/10.1245\/s10434-022-12643-5.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"1364_CR39","doi-asserted-by":"publisher","first-page":"6936","DOI":"10.1245\/s10434-022-12100-3","volume":"29","author":"LC Borbon","year":"2022","unstructured":"Borbon LC, Tran CG, Sherman SK, Ear PH, Chandrasekharan C, Bellizzi AM, et al. Is there a role for surgical resection of grade 3 neuroendocrine neoplasms? Ann Surg Oncol. 2022;29(11):6936\u201346. https:\/\/doi.org\/10.1245\/s10434-022-12100-3.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1364_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1245\/s10434-022-12644-4","volume":"30","author":"IA Ziogas","year":"2023","unstructured":"Ziogas IA, Dillon JS, Chandrasekharan C, Howe JR. Aso author reflections: surgical resection should be considered in the multidisciplinary care of patients with grade 3 gastroenteropancreatic neuroendocrine neoplasms. Ann Surg Oncol. 2023;30(1):161\u20132. https:\/\/doi.org\/10.1245\/s10434-022-12644-4.","journal-title":"Ann Surg Oncol"},{"key":"1364_CR41","doi-asserted-by":"publisher","unstructured":"Perez K, Del Rivero J, Kennedy EB, Basu S, Chauhan A, Connolly HM et al. Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. JCO Oncol Pract. 2025:OP2500133. https:\/\/doi.org\/10.1200\/OP-25-00133","DOI":"10.1200\/OP-25-00133"},{"issue":"13","key":"1364_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35871","volume":"131","author":"DG Su","year":"2025","unstructured":"Su DG, Brown LM, Bansal VV, Bakkila B, Concors SJ, Turaga KK, et al. Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms. Cancer. 2025;131(13):e35871. https:\/\/doi.org\/10.1002\/cncr.35871.","journal-title":"Cancer"},{"issue":"11","key":"1364_CR43","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/cncr.32865","volume":"126","author":"Chicago Consensus Working G","year":"2020","unstructured":"Chicago Consensus Working G. The Chicago consensus on peritoneal surface malignancies: management of neuroendocrine tumors. Cancer. 2020;126(11):2561\u20135. https:\/\/doi.org\/10.1002\/cncr.32865.","journal-title":"Cancer"},{"issue":"6","key":"1364_CR44","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1245\/s10434-020-08323-x","volume":"27","author":"Chicago Consensus Working G","year":"2020","unstructured":"Chicago Consensus Working G. The Chicago consensus on peritoneal surface malignancies: palliative care considerations. Ann Surg Oncol. 2020;27(6):1798\u2013804. https:\/\/doi.org\/10.1245\/s10434-020-08323-x.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"1364_CR45","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1159\/000509220","volume":"111","author":"L Benhaim","year":"2021","unstructured":"Benhaim L, Faron M, Hadoux J, Gelli M, Sourrouille I, Burtin P, et al. Long-term results after surgical resection of peritoneal metastasis from neuroendocrine tumors. Neuroendocrinology. 2021;111(6):599\u2013608. https:\/\/doi.org\/10.1159\/000509220.","journal-title":"Neuroendocrinology"},{"issue":"14","key":"1364_CR46","doi-asserted-by":"publisher","first-page":"e71043","DOI":"10.1002\/cam4.71043","volume":"14","author":"C Peritoneal","year":"2025","unstructured":"Expert Panel Management of, Peritoneal C, Kennedy T, Singh S, Abood G, Christenson E, Anker CJ, et al. Executive summary of the American radium society appropriate use criteria for the management of peritoneal carcinomatosis from different tumor origins: systematic review and guidelines. Cancer Med. 2025;14(14):e71043. https:\/\/doi.org\/10.1002\/cam4.71043.","journal-title":"Cancer Med"},{"issue":"3","key":"1364_CR47","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel WJ, Koole SN, Sikorska K, van Schagen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1708618.","journal-title":"N Engl J Med"},{"issue":"1","key":"1364_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.surg.2013.05.030","volume":"155","author":"D Elias","year":"2014","unstructured":"Elias D, David A, Sourrouille I, Honore C, Goere D, Dumont F, et al. Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intra-abdominal metastases). Surgery. 2014;155(1):5\u201312. https:\/\/doi.org\/10.1016\/j.surg.2013.05.030.","journal-title":"Surgery"},{"issue":"7","key":"1364_CR49","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.ejso.2022.03.019","volume":"48","author":"R Hajjar","year":"2022","unstructured":"Hajjar R, Mercier F, Passot G, Pasquer A, Gelli M, Levine EA, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis. Eur J Surg Oncol. 2022;48(7):1626\u201330. https:\/\/doi.org\/10.1016\/j.ejso.2022.03.019.","journal-title":"Eur J Surg Oncol"},{"issue":"28","key":"1364_CR50","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27(28):4656\u201363. https:\/\/doi.org\/10.1200\/JCO.2009.22.8510.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1364_CR51","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1316158.","journal-title":"N Engl J Med"},{"issue":"10022","key":"1364_CR52","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(15)00817-X.","journal-title":"Lancet"},{"issue":"2","key":"1364_CR53","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/curroncol29020046","volume":"29","author":"T Al-Toubah","year":"2022","unstructured":"Al-Toubah T, Morse B, Strosberg J. Efficacy of capecitabine and temozolomide in small bowel (Midgut) neuroendocrine tumors. Curr Oncol. 2022;29(2):510\u20135. https:\/\/doi.org\/10.3390\/curroncol29020046.","journal-title":"Curr Oncol"},{"issue":"7","key":"1364_CR54","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa2403991","volume":"392","author":"JA Chan","year":"2025","unstructured":"Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S, et al. Phase 3 trial of Cabozantinib to treat advanced neuroendocrine tumors. N Engl J Med. 2025;392(7):653\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2403991.","journal-title":"N Engl J Med"},{"issue":"6","key":"1364_CR55","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1470-2045(17)30336-4","volume":"18","author":"J Tseng","year":"2017","unstructured":"Tseng J, Bryan DS, Poli E, Sharma M, Polite BN, Turaga KK. Under-representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. Lancet Oncol. 2017;18(6):711\u20132. https:\/\/doi.org\/10.1016\/S1470-2045(17)30336-4.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1364_CR56","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"16","key":"1364_CR57","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","volume":"23","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23(16):4617\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2743.","journal-title":"Clin Cancer Res"},{"issue":"10446","key":"1364_CR58","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"S Singh","year":"2024","unstructured":"Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high\u2011dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2\u20133, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024;403(10446):2807\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(24)00701-3.","journal-title":"Lancet"},{"issue":"6","key":"1364_CR59","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1159\/000503144","volume":"110","author":"E Merola","year":"2020","unstructured":"Merola E, Prasad V, Pascher A, Pape UF, Arsenic R, Denecke T, et al. Peritoneal carcinomatosis in Gastro-Entero-Pancreatic neuroendocrine neoplasms: clinical impact and effectiveness of the available therapeutic options. Neuroendocrinology. 2020;110(6):517\u201324. https:\/\/doi.org\/10.1159\/000503144.","journal-title":"Neuroendocrinology"},{"key":"1364_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07212-3","author":"N Poterszman","year":"2025","unstructured":"Poterszman N, Baltzinger P, Mamulashvili Bessac D, Pham Van F, Goichot B, Mertz L, et al. Neuroendocrine peritoneal disease and [(177)Lu]DOTATATE peptide receptor radionuclide therapy: a therapeutic challenge with potential clinical complications. Eur J Nucl Med Mol Imaging. 2025. https:\/\/doi.org\/10.1007\/s00259-025-07212-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1364_CR61","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1530\/ERC-16-0524","volume":"24","author":"T Brabander","year":"2017","unstructured":"Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, de Herder WW, Feelders RA, et al. Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate. Endocr Relat Cancer. 2017;24(5):243\u201351. https:\/\/doi.org\/10.1530\/ERC-16-0524.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"1364_CR62","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2967\/jnumed.120.242875","volume":"62","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Al-Toubah T, Pelle E, Smith J, Haider M, Hutchinson T, et al. Risk of bowel obstruction in patients with mesenteric or peritoneal disease receiving peptide receptor radionuclide therapy. J Nucl Med. 2021;62(1):69\u201372. https:\/\/doi.org\/10.2967\/jnumed.120.242875.","journal-title":"J Nucl Med"},{"issue":"5","key":"1364_CR63","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s11912-025-01668-0","volume":"27","author":"A Spyroglou","year":"2025","unstructured":"Spyroglou A, Violetis O, Iliakopoulos K, Vezakis A, Alexandraki K. Mesenteric fibrosis in neuroendocrine neoplasms: a systematic review of new thoughts on causation and potential treatments. Curr Oncol Rep. 2025;27(5):642\u201355. https:\/\/doi.org\/10.1007\/s11912-025-01668-0.","journal-title":"Curr Oncol Rep"},{"issue":"11","key":"1364_CR64","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1080\/14796694.2025.2485650","volume":"21","author":"US Grewal","year":"2025","unstructured":"Grewal US, Gbolahan OB, Takalkar AM, Halperin DM. Alpha radioligand therapy in neuroendocrine neoplasms: current landscape and spotlight on RYZ101. Future Oncol. 2025;21(11):1357\u201363. https:\/\/doi.org\/10.1080\/14796694.2025.2485650.","journal-title":"Future Oncol"},{"issue":"18","key":"1364_CR65","first-page":"3963","volume":"57","author":"PK Narayanan","year":"1997","unstructured":"Narayanan PK, Goodwin EH, Lehnert BE. Alpha particles initiate biological production of superoxide anions and hydrogen peroxide in human cells. Cancer Res. 1997;57(18):3963\u201371.","journal-title":"Cancer Res"},{"key":"1364_CR66","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17362-1","author":"VV Bansal","year":"2025","unstructured":"Bansal VV, Godfrey EL, Sadjadi J, Bello RJ, Kwakman R, Abreu AA, et al. Consensus guideline for the management of malignant Gastrointestinal obstruction in patients with peritoneal surface malignancies. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-025-17362-1.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1364_CR67","first-page":"1","volume":"4","author":"S Das","year":"2019","unstructured":"Das S, Shi C, Koyama T, Huang Y, Gonzalez R, Idrees K, et al. Peritoneal carcinomatosis in Well-Differentiated Small-Intestinal neuroendocrine tumors with mesenteric tumor deposits. J Med Surg Pathol. 2019;4(1):1\u201310.","journal-title":"J Med Surg Pathol"},{"issue":"9","key":"1364_CR68","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s40618-024-02330-5","volume":"47","author":"M Tsoli","year":"2024","unstructured":"Tsoli M, Wilson H, Armonis P, Kamieniarz L, Thuringer J, Mirnezami R, et al. Peritoneal metastases in patients with neuroendocrine neoplasms: a challenging site of metastases with clinical and prognostic implications. J Endocrinol Invest. 2024;47(9):2295\u2013303. https:\/\/doi.org\/10.1007\/s40618-024-02330-5.","journal-title":"J Endocrinol Invest"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01364-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01364-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01364-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:46:04Z","timestamp":1763642764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01364-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1364"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01364-y","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The authors have no COI nor disclosures for this review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"COI\/Disclosure Statement"}}]}}